html
BI 201335; Positive Phase 2 results
Boehringer Ingelheim’s investigational Hepatitis C protease inhibitor
Sunday, April 3, 2011
Posted by New HCV Drugs
FILE UNDER BI 201335, EASL
Positive Phase 2 results reported with Boehringer Ingelheim’s investigational HCV protease inhibitor in both previously treated and untreated patients
BERLIN, Germany, and RIDGEFIELD, CT, April 1, 2011 – New data presented today at the 46th Annual Meeting of the European Association for the Study of the Liver (E